Comparative Pharmacology
Head-to-head clinical analysis: QUTENZA versus SALONPAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUTENZA versus SALONPAS.
QUTENZA vs SALONPAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QUTENZA (capsaicin) is a transient receptor potential vanilloid 1 (TRPV1) agonist. It selectively binds to TRPV1 receptors on cutaneous nociceptors, causing initial excitation followed by defunctionalization and reduced sensitivity to pain.
Salicylate topical analgesic; inhibits cyclooxygenase (COX) and prostaglandin synthesis, providing local anti-inflammatory and analgesic effects.
Topical patch applied to painful area for 60 minutes every 3 months (up to 4 patches per application).
Apply one 10 cm x 14 cm patch topically to affected area every 12 hours; maximum 2 patches daily.
None Documented
None Documented
6.5 hours (range 5-8 hours) for systemic capsaicin; transient due to rapid metabolism. Clinically, local effects persist beyond systemic clearance.
Approximately 2-3 hours for salicylate at therapeutic concentrations; increases dose-dependently (e.g., >20 hours at anti-inflammatory doses) due to saturation of hepatic metabolism. Clinical context: extended half-life at high doses requires monitoring for accumulation.
Primarily renal; capsaicin and metabolites excreted in urine, with <1% unchanged. Fecal elimination accounts for <5%.
Primarily renal excretion of glucuronide conjugates and unchanged drug; approximately 50-60% excreted in urine as glucuronide conjugates, 10-20% as unchanged salicylate, and <5% as salicyluric acid. Biliary excretion is minimal, with less than 5% eliminated in feces.
Category C
Category C
Topical Analgesic
Topical Analgesic